Vortex Technology, LLC

Bio-sphere Technology

Other

See/shell Biotechnology, Inc.

Nanologix Research, Inc.

Harvard Scientific Corporation

The Upjohn Co.

Bio Technology, LLC

Endovasc Ltd., Inc.

Natur-all Systems, Inc.

Jackie R See

William E Shell

Michael J Snyder

Darryl M See

Elliot B Lander

John Wallace Matthews

David P Summers

Carl J Buczek

William Shell

The invention relates to a method and system for the environmental remediation of materials that are contaminated with heavy minerals, such as heavy metals. The invention finds utility in removing heavy minerals from materials such as soils, sediments, mine tailings and ores. The invention provides a means for removing heavy minerals from contaminated materials without the use of water while reducing the generation of dust. Thus, the invention provides an environmentally friendly method for the remediation of sites that are contaminated with heavy minerals.

System and method for suppressing dust during the collection of heavy minerals

System and method for collecting heavy minerals

A medicament for treating cystitis and a method of treatment are provided. An agent to repair the damaged glycosaminoglycan ('GAG') layers lining the urothelium, noted in cystitis, such as pentosan polysulfate, hyaluronic acid, chondroitin, etc., is provided in a liposomal carrier. Cystitis is treated by intravesically administering to a patient a therapeutically effective dose of the medicament.

Method and composition for treating cystitis

Systems and methods for the environmental remediation of materials contaminated with heavy minerals

A device and methods for the real-time monitoring of stem cells in a stem cell transplant. The device comprises a linear member and particle detection device configured to occupy the lumen of a catheter while the catheter is in place to administer a stem cell transplant to a delivery site in the body of a patient. Monitoring of the stem cells permits the device to provide signals to a computer processor for the determination of one or more characteristics of stem cells in the stem cell transplant.

Device and methods for monitoring the administration of a stem cell transplant

A method is provided for inducing a systemic immune response to an antigen selected from inactivated HIV I and HIV II antigens in a mammal. The method comprises orally administering lyophilized multilaminar liposomes containing the antigen. The liposomes have a size of from 20 nm to 20 microns. The antigen-containing liposomes are absorbed in the Peyer's patches of the gut. Sufficient antigen-containing liposomes are taken up by macrophages in the Peyer's patches to induce a systemic immune response to the antigen.

Method for inducing a systemic immune response to an HIV antigen

A method is provided for inducing a systemic immune response to an antigen selected from hepatitis B and hepatitis C antigens in a mammal. The method comprises orally administering lyophilized multilamellar liposomes containing the antigen. The liposomes have a size of from 20 nm to 20 microns. The antigen-containing liposomes are absorbed in the Peyer's patches of the gut. Sufficient antigen-containing liposomes are taken up by macrophages in the Peyer's patches to induce a systemic immune response to the antigen.

Method for inducing a systemic immune response to a hepatitis antigen

A method for treating female sexual dysfunction or for female sexual enhancement comprises administering to the vagina a composition comprising a prostanoid compound having a vasodilating effect in a pharmaceutically acceptable vehicle. The amount of prostanoid compound administered ranges from about 0.05 mg to about 3 mg, and preferably from about 0.125 mg to about 1 mg. Preferably the prostanoid compound is prostaglandin E-1 and the pharmaceutically acceptable vehicle is methylcellulose.

Methods for treating female sexual dysfunction

A method is provided for inducing a systemic immune response to an antigen in a mammal. The method comprises orally administering lyophilized multilamellar liposomes containing the antigen. The liposomes have a size of from 20 nm to 20 microns. The antigen-containing liposomes are absorbed in the Peyer's patches of the gut. Sufficient antigen-containing liposomes are taken up by macrophages in the Peyer's patches to induce a systemic immune response to the antigen.

Method for inducing a systemic immune response to an antigen

X-ray contrast media encapsulated within 50 nm to 10 .mu.m microspheres were shown to be a superior contrast agent for CT imaging of liver tumors. Use of the encapsulated agent resulted in significant improvement in the liver to tumor contrast ratio in CT images over prior art contrast media. The encapsulated media contrast also resulted in sustained contrast enhancement 1 hr after administration, providing the opportunity to use a lesser x-ray exposure in a single scan to discriminate cancerous tissue from normal surrounding tissue.

Methods of preparing micro encapsulated agents for use in the detection

A stent or vascular graft for supporting a blood vessel or organ lumen is coated with a biodegradable, resorbable and hemocompatible surface substrate. Biologically active microspheres which controllably release the biologically active agent into the vessel wall or organ to inhibit restenosis of the stent is embedded in the stent substrate. The biologically active microspheres include encapsulated PGE1 in a water soluble polyethylene glycol mix, which over a period of time dissolves and releases the PGE1 into the vessel wall or organ.

Composition and method for making a biodegradable drug delivery stent

A composition for inhibiting absorption of fat and cholesterol from the gut and a method for making and using the composition. The composition comprises .beta.-sitosterol bound irreversibly to pectin to form a .beta.-sitosterol/pectin complex.

Dietary supplement incorporating .beta.-sitosterol and pectin

A method for the treatment of erectile dysfunction comprises instilling intra meatally an aqueous solution containing prostaglandin-containing liposomes and a detergent for lysing the liposomes. A pharmaceutical composition for treating erectile dysfunction comprises a two-component system. The first component comprises a predetermined amount of lyophilized prostaglandin-containing liposomes. The second component comprises a predetermined volume of an aqueous solution containing a detergent, preferably PEG(9) octylphenyl ether, for lysing the liposomes. Dissolution of the lyophilized prostaglandin-containing liposomes yields a liquid composition suitable for application to the penis, preferably intra meatally, to effect erection.

Growing community of inventors

Fullerton, CA, United States of America

Jackie R See